The role of the urinary microbiome on male benign prostatic hyperplasia (BPH) and its management using probiotic supplementation: a narrative review.

N Schifano, P Capogrosso, S Baldini, A Villano, G Antonini, F Deho'
{"title":"The role of the urinary microbiome on male benign prostatic hyperplasia (BPH) and its management using probiotic supplementation: a narrative review.","authors":"N Schifano, P Capogrosso, S Baldini, A Villano, G Antonini, F Deho'","doi":"10.26355/eurrev_202412_36978","DOIUrl":null,"url":null,"abstract":"<p><p>Benign prostatic hyperplasia (BPH) is highly prevalent and associated with a significant impact on individuals' well-being. Initial management involves various medications, but their benefits can be limited by side effects, particularly concerning young people. In this context, novel and better-tolerated therapeutic strategies have been proposed, thus including the modulation of the gut microbiome through probiotic ingestion. We aimed to examine the available evidence linking the urinary microbiome to lower urinary tract symptoms (LUTS) and to evaluate the possible usefulness of probiotic supplementation as a novel treatment option for LUTS/BPH. A narrative review design was preferred to fulfill our purpose. The search strategy included a range of terms, e.g., \"microbiome,\" \"microbiota,\" \"urobiome,\" AND/OR \"probiotics\" AND \"benign prostatic hyperplasia,\" \"benign prostatic enlargement,\" \"lower urinary tract symptoms.\" A range of studies aimed to investigate the possible impact of urinary microbiome on BPH. Gut and/or urinary dysbiosis can alter the gut permeability and initiate/maintain inflammatory and oxidative processes in the prostate, which may contribute to the cell-hyper-proliferation leading to BPH. The modulation of the urinary and/or gut microbiome through probiotic supplementation seems to provide levels of clinical effectiveness in the management of BPH. Although different probiotics have been tested, a combination of B. Longum and F. Psychaerophilum seems to be particularly promising due to their capability of modulating both the inflammatory pathway and the intestinal barrier permeability. Gut and/or urinary microbiome dysbiosis is most likely contributing to the BPH pathogenesis. Even though only scarce evidence on the potential usefulness of probiotic supplementation in the management of BPH is currently available, the available studies seem to provide encouraging results. Further prospective trials are warranted in order to confirm these findings and to clarify which probiotic strains are more suitable for supplementation in this setting.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 23","pages":"4671-4679"},"PeriodicalIF":3.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European review for medical and pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26355/eurrev_202412_36978","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Benign prostatic hyperplasia (BPH) is highly prevalent and associated with a significant impact on individuals' well-being. Initial management involves various medications, but their benefits can be limited by side effects, particularly concerning young people. In this context, novel and better-tolerated therapeutic strategies have been proposed, thus including the modulation of the gut microbiome through probiotic ingestion. We aimed to examine the available evidence linking the urinary microbiome to lower urinary tract symptoms (LUTS) and to evaluate the possible usefulness of probiotic supplementation as a novel treatment option for LUTS/BPH. A narrative review design was preferred to fulfill our purpose. The search strategy included a range of terms, e.g., "microbiome," "microbiota," "urobiome," AND/OR "probiotics" AND "benign prostatic hyperplasia," "benign prostatic enlargement," "lower urinary tract symptoms." A range of studies aimed to investigate the possible impact of urinary microbiome on BPH. Gut and/or urinary dysbiosis can alter the gut permeability and initiate/maintain inflammatory and oxidative processes in the prostate, which may contribute to the cell-hyper-proliferation leading to BPH. The modulation of the urinary and/or gut microbiome through probiotic supplementation seems to provide levels of clinical effectiveness in the management of BPH. Although different probiotics have been tested, a combination of B. Longum and F. Psychaerophilum seems to be particularly promising due to their capability of modulating both the inflammatory pathway and the intestinal barrier permeability. Gut and/or urinary microbiome dysbiosis is most likely contributing to the BPH pathogenesis. Even though only scarce evidence on the potential usefulness of probiotic supplementation in the management of BPH is currently available, the available studies seem to provide encouraging results. Further prospective trials are warranted in order to confirm these findings and to clarify which probiotic strains are more suitable for supplementation in this setting.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
泌尿微生物组在男性良性前列腺增生(BPH)中的作用及其使用益生菌补充剂的管理:叙述性回顾。
良性前列腺增生(BPH)是非常普遍的,并与个人的福祉显著影响。最初的治疗包括各种药物,但它们的益处可能受到副作用的限制,特别是对年轻人。在这种情况下,新的和更好耐受的治疗策略被提出,因此包括通过益生菌摄入调节肠道微生物组。我们的目的是检查尿微生物组与下尿路症状(LUTS)联系的现有证据,并评估益生菌补充作为LUTS/BPH的新治疗选择的可能有用性。叙述性回顾设计更适合我们的目的。搜索策略包括一系列术语,例如“微生物组”、“微生物群”、“泌尿组”和/或“益生菌”和“良性前列腺增生”、“良性前列腺增大”、“下尿路症状”。一系列的研究旨在调查泌尿微生物群对前列腺增生的可能影响。肠道和/或泌尿系统失调可以改变肠道通透性,启动/维持前列腺的炎症和氧化过程,这可能有助于细胞过度增殖,导致前列腺增生。通过补充益生菌调节尿液和/或肠道微生物群似乎在BPH管理中提供了临床有效性水平。虽然已经测试了不同的益生菌,但长芽胞杆菌和嗜气荚膜菌的组合似乎特别有希望,因为它们具有调节炎症途径和肠屏障通透性的能力。肠道和/或泌尿系统微生物群失调最有可能导致前列腺增生。尽管目前只有很少的证据表明益生菌补充剂在BPH管理中的潜在作用,但现有的研究似乎提供了令人鼓舞的结果。进一步的前瞻性试验是必要的,以证实这些发现,并澄清哪些益生菌菌株更适合在这种情况下补充。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.30
自引率
6.10%
发文量
906
审稿时长
2-4 weeks
期刊介绍: European Review for Medical and Pharmacological Sciences, a fortnightly journal, acts as an information exchange tool on several aspects of medical and pharmacological sciences. It publishes reviews, original articles, and results from original research. The purposes of the Journal are to encourage interdisciplinary discussions and to contribute to the advancement of medicine. European Review for Medical and Pharmacological Sciences includes: -Editorials- Reviews- Original articles- Trials- Brief communications- Case reports (only if of particular interest and accompanied by a short review)
期刊最新文献
Long-term blood pressure control assessment using time spent in therapeutic range among Saudi patients. Predictive factors for lack of neurological improvement in acute stroke patients without large vessel occlusion treated with low-dose thrombolysis and screened with 3T MRI. Retraction Note: Functional role of SIRT1-induced HMGB1 expression and acetylation in migration, invasion and angiogenesis of ovarian cancer. Retraction Note: MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9. The role of the urinary microbiome on male benign prostatic hyperplasia (BPH) and its management using probiotic supplementation: a narrative review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1